BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36727535)

  • 1. Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable-risk prostate cancer.
    Huang D; Ruan X; Huang J; Zhang N; Jiang G; Gao Y; Xu D; Na R
    Cancer Med; 2023 Apr; 12(8):9868-9878. PubMed ID: 36727535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015.
    Butler SS; Loeb S; Cole AP; Zaslowe-Dude C; Muralidhar V; Kim DW; Schaeffer EM; Trinh QD; Nguyen PL; Mahal BA
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):179-183. PubMed ID: 31591454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations.
    Jeong CW; Washington SL; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
    Eur Urol; 2020 Sep; 78(3):335-344. PubMed ID: 31980309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
    Mahal AR; Butler S; Franco I; Muralidhar V; Larios D; Pike LRG; Zhao SG; Sanford NN; Dess RT; Feng FY; D'Amico AV; Spratt DE; Yu JB; Nguyen PL; Rebbeck TR; Mahal BA
    Cancer; 2019 Oct; 125(19):3338-3346. PubMed ID: 31251398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
    Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
    Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison of survival between active surveillance or watchful waiting and focal laser ablation in patients with low-risk prostate cancer.
    Li JK; Zhang CC; Qiu S; Jin K; Cai BY; Yuan QM; Xiong XY; Tang LS; Jin D; Zhou XH; Bao YG; Yang L; Wei Q
    Asian J Androl; 2022; 24(5):494-499. PubMed ID: 35102899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
    Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
    Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
    J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overtreatment and Underutilization of Watchful Waiting in Men With Limited Life Expectancy: An Analysis of the Michigan Urological Surgery Improvement Collaborative Registry.
    Singhal U; Tosoian JJ; Qi J; Miller DC; Linsell SM; Cher M; Lane B; Cotant M; Montie JE; Bazzi W; Jafri M; Rosenberg B; George AK;
    Urology; 2020 Nov; 145():190-196. PubMed ID: 32777369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
    Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
    Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database.
    Yuan QM; Lin TH; Jin K; Qiu S; Zhou XH; Jin D; Li JK; Yang L; Wei Q
    Asian J Androl; 2022; 24(3):305-310. PubMed ID: 34596600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.
    Hu S; Chang CP; Snyder J; Deshmukh V; Newman M; Date A; Galvao C; Porucznik CA; Gren LH; Sanchez A; Lloyd S; Haaland B; O'Neil B; Hashibe M
    JCO Clin Cancer Inform; 2023 Sep; 7():e2300083. PubMed ID: 37988640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
    Herden J; Weissbach L
    World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
    Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
    Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial Disparities in Active Surveillance for Prostate Cancer.
    Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
    J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.